This early phase I study collects blood samples and monitors the levels of pembrolizumab and nivolumab as they move through the body in patients with melanoma and/or non-small cell lung cancer. Pembrolizumab and nivolumab are a monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Studying samples of blood in the laboratory from patients receiving pembrolizumab and nivolumab may help doctors learn more about the effects of pembrolizumab and nivolumab on cells. It may also help doctors understand how well patients respond to treatment. Information from this study may be used in the future to guide physicians to make dosage adjustments based on serum concentrations of drug to minimize adverse side effects and maximize the effect of the drug.
PRIMARY OBJECTIVE: I. To perform a steady-state PK study on patients who are taking monoclonal antibody therapy (25 patients starting pembrolizumab and 25 patients starting nivolumab for melanoma or non-small cell lung cancer). II. Develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay to measure pembrolizumab and nivolumab in serum. III. Measure patient samples for pembrolizumab/nivolumab at various clinical time points. IV. Use the pharmacokinetic data (drug concentrations) to determine the area under the curve (AUC), maximum observed serum concentration (Cmax), clearance, half-life (t1/2), and trough steady-state drug concentrations. V. Compare the data to the clinical efficacy (defined using Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 criteria)1, as well as, presence of auto-immune side effects using multiple variable regression modeling in Statistical Analysis System (SAS) version (v)9.4 or other statistical software. OUTLINE: Patients undergo collection of blood samples and have medical records reviewed on study.
Study Type
OBSERVATIONAL
Enrollment
13
Undergo collection of blood samples
Medical records are reviewed
Ancillary studies
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Development and validation of a laboratory developed test (LDT) using liquid chromatography tandem mass spectrometry to measure pemborlizumab and nivolumab.
Verify the accuracy, precision, linearity, sensitivity and specificity of a mass spectrometry assay for pembrolizumab and nivolumab in serum
Time frame: Up to 1 year
Measurement of patient samples for pembrolizumab
Using a validated LDT liquid chromatography tandem mass spectrometry assay measure the concentration of pembrolizumab in serum.
Time frame: Through study completion at several time points, an average of 3 weeks after taking pembrolizumab for at least 21 weeks.
Measurement of patient samples for nivolumab
Using a validated LDT liquid chromatography tandem mass spectrometry assay measure the concentration of nivolumab in serum.
Time frame: Through study completion at several time points, an average of 1 month after taking nivolumab for at least 14 weeks
Correlation of steady-state concentrations of pembrolizumab correlate with clinical efficacy and/or toxicity
Will assess if therapeutic drug monitoring correlates with efficacy and/or toxicity of pembrolizumab. Concentrations in serum will be determined using a LDT mass spectrometry assay.
Time frame: Through study completion, an average of 3 weeks after taking pembrolizumab for at least 21 weeks.
Correlation of steady-state concentrations of nivolumab correlate with clinical efficacy
Will assess if therapeutic drug monitoring correlates with efficacy and/or toxicity of nivolumab. Concentrations in serum will be determined using a LDT mass spectrometry assay.
Time frame: Through study completion, an average of 1 month after taking nivolumab for at least 14 weeks
Clinical efficacy
Tumor response will be determined using Response Evaluation Criteria in Solid Tumors1.1 criteria. Clinical efficacy defined as achieving an objective response (complete response or partial response) versus stable disease, or disease progression.
Time frame: After 6 months (24 weeks or more) of treatment
Presence of auto-immune side effects
Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse events, version 4.0. Investigators will indicate if it was potentially immune related (i.e. grade 3-4 adverse events such as pneumonitis, diarrhea/colitis, hypophysitis/adrenal insufficiency, hyper/hypothyroidism, autoimmune hepatitis, severe skin reactions, nephritis/kidney failure, uveitis, myositis) in combination with other basic laboratory tests that are routinely monitored. Will use multiple variable regression modeling in Statistical Analysis System version 9.4 or other statistical software.
Time frame: Through study completion, an average of 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.